COVID-19 vaccine from Anhui earns conditional approval
Share - WeChat
China has given conditional approval for a recombinant protein subunit COVID-19 vaccine developed by domestic company Anhui Zhifei Longcom Biopharmaceutical, the National Medical Products Administration said on Wednesday.
The vaccine uses purified pieces of the virus' protein to trigger an immune response. It is the first vaccine based on this technology to be approved by the top drug regulator.
In total, five COVID-19 vaccines have been approved for public use in China so far.
- Auto leaders optimistic as Anhui emerges as industry hub
- Shanghai boosts services for inbound travelers
- China's Longli River Bridge: a marvel of engineering
- Visually impaired programmer revolutionizes braille translation in Xizang
- Innovative 3D printing transforms rural housing in Hubei
- Street stall to success: A stinky tofu journey